ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions
Solid Tumors
Interventions
DRUG

ME-344

"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."

DRUG

Topotecan

Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.

Trial Locations (10)

29425

Medical University of South Carolina, Charleston

37203

Tennessee Oncology, PLLC, Nashville

45242

Oncology Hematology Care, Cincinnati

60611

Northwestern University, Chicago

73104

University of Oklahoma, Oklahoma City

80045

University of Colorado Cancer Center, Aurora

85258

Pinnacle Oncology Hematology, Scottsdale

98109

University of WA Seattle Cancer Care Alliance, Seattle

W2 1NY

The Bays St Mary's Hospital, London

WIG 6AD

Sarah Cannon Research Instititute UK, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

lead

MEI Pharma, Inc.

INDUSTRY